Ipamorelin is the cleanest growth-hormone switch the lab has built — and the body-composition story is the most interesting part.

Start here

Ipamorelin is a small synthetic peptide — five amino acids — designed to make the pituitary gland release a pulse of growth hormone (the body's main signal for repair, lean tissue, and metabolism). What makes it special is precision: it flips the growth-hormone switch without dragging up stress hormones like cortisol the way older peptides did ^[1]. People are most curious about what that does to the body: leaner build, better recovery, deeper sleep. The honest answer is that the strongest data is from animals, and the body-composition effects in people are reported but not proven in trials. Human testing is thin and, so far, the one real trial it had did not hit its goal ^[3]. It has never been approved as a medicine anywhere ^[3]. Here we read the record straight — the wins, the gaps, and the legal status — and what people report, including the downsides, is on the effects page.

What ipamorelin actually does to body composition

Ipamorelin works by activating the ghrelin receptor (GHS-R1a) on the pituitary — the same receptor your natural "hunger hormone" uses — and that triggers a short, sharp burst of growth hormone ^[1]. Growth hormone is the upstream lever for body composition: more lean tissue, mobilization of fat, and (through the liver) the production of IGF-1, a growth-signaling molecule that carries out many of GH's downstream jobs.

The body-composition signal shows up early in the animal record. An oral analog built directly from ipamorelin's scaffold produced clear body-weight gain over 14 days in rats while keeping the same GH-specific profile ^[7]. In mice, two weeks of ipamorelin raised body weight, fat-pad mass, and leptin — and it did so in both growth-hormone-deficient and normal animals, which means part of the effect runs on a track separate from GH itself ^[9]. That is a more interesting finding than the marketing version: the body-composition story is not purely a GH story.

One nuance the honest record keeps front and center: in short rodent studies, ipamorelin grew bone and tissue without measurably raising circulating IGF-1 ^[4]. The GH pulse can do local work before the systemic IGF-1 number ever moves. Anyone reading ipamorelin as a simple "GH up, IGF-1 up, lean up" equation is reading a cleaner story than the data tells.

What the human evidence shows — and where it stops

Here is the part most write-ups skip. Ipamorelin has been in humans, but barely, and the results were not a win. Its only published Phase 2 randomized trial gave 0.03 mg/kg intravenously twice daily to 114 adults recovering from bowel surgery — and it missed its primary endpoint: time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo, a gap that did not reach statistical significance ^[3]. No serious ipamorelin-specific safety alarm fired in that short window, but efficacy was not demonstrated.

The other solid human dataset is pharmacology, not outcomes: in healthy male volunteers, ipamorelin behaved predictably, with a terminal half-life of about 2 hours and a single growth-hormone pulse peaking roughly 40 minutes after dosing ^[2]. That is the entire well-controlled human picture — a clean pharmacokinetic profile and one negative efficacy trial. Everything else marketed as a benefit traces back to animals or to community reports, not to controlled human outcomes. Read the full breakdown of the Ipamorelin research.

The honest read on "legal"

The word in this site's name deserves a straight answer. Ipamorelin is not FDA-approved as a drug for any use — it was investigated, most notably for post-surgical bowel recovery, and never approved ^[3]. In 2024 the FDA removed ipamorelin acetate from Category 2 of its interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening the path for compounding pharmacies. In sport, it is prohibited at all times under the World Anti-Doping Agency's category S2, and accredited labs can detect it in urine. None of this is legal advice — it is the regulatory record, read as written, so you can do your own due diligence with clear eyes.

How to read this site

Every number here is tied to a study you can check. The effects page covers what people in research-use communities actually report — benefits and side effects, clearly labeled as anecdotal. The research page digs into mechanism, the human trial, and how ipamorelin compares with sermorelin, tesamorelin, and its frequent partner CJC-1295. Two body-composition deep dives answer the questions people search most: does ipamorelin cause weight gain and ipamorelin benefits. The dosage page covers what was studied, in which species, by which route — never a human prescription. The full Ipamorelin references list closes it out.